What's Going On With Cancer-Focused Immix Biopharma Stock Today?

Immix Biopharma Inc IMMX announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy

The updated dataset consists of 63 multiple myeloma patients.

95% overall response rate (36 of 38 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma who were not exposed to prior BCMA-targeted therapy, producing a median progression-free survival (mPFS) of 12.9 months.

Also Read: Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis.

90% overall response rate (45 of 50 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma.

58% complete response rate (29 out of 50 patients at the therapeutic dose of 800 million CAR+T cells)

The overall response rates for each dose level were 50%, 86%, and 90%, respectively.

Favorable NXC-201 safety data support the potential for NXC-201, if ultimately approved, to reduce hospitalization, with an opportunity for use as outpatient CAR-T cell therapy, potentially reducing related hospitalization costs by up to 80%.

Price Action: IMMX shares are up 23.40% at $4.22 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!